Table 3.
Cognitive test results for each cohort
| Cognitive test | A. Study cohort | B. No progress in CDR | C. No amyloid or tau pathology | D. No vascular pathology | E. No measurable in vivo pathology |
|---|---|---|---|---|---|
| ADAS-delayed recall | 1.98 (1.93) | 1.79 (1.72) | 1.80 (1.78) | 1.81 (1.80) | 1.59 (1.56) |
| ADAS naming | 0.38 (0.79) | 0.34 (0.74) | 0.36 (0.79) | 0.30 (0.75) | 0.24 (0.68) |
| Animal Fluency | 21.7 (5.5) | 22.1 (5.4) | 22.0 (5.5) | 22.4 (5.3) | 23.0 (5.3) |
| AQT | 66.0 (12.9) | 65.1 (12.3) | 65.8 (12.9) | 63.8 (12.0) | 63.3 (11.1) |
| Stroop | 28.9 (7.4) | 28.5 (7.0) | 28.6 (7.5) | 27.5 (6.9) | 26.9 (6.7) |
| TMT A | 46.0 (17.0) | 45.6 (17.1) | 45.6 (16.9) | 43.0 (14.8) | 41.0 (12.0) |
| TMT B | 104.4 (50.8) | 101.8 (49.4) | 101.9 (49.0) | 97.1 (44.7) | 90.0 (36.5) |
| SDMT | 37.0 (8.4) | 37.5 (8.3) | 37.5 (8.5) | 38.4 (8.3) | 39.1 (8.0) |
Data are shown as mean (SD). A: The entire population. B: No progress in Clinical Dementia Rating (CDR) over 2 years. C: No preclinical AD (i.e., CSF Aβ42/40 and P-tau not abnormal). D: No vascular pathology. E: No measurable pathology (i.e., no AD pathology, cerebrovascular pathology or increased NfL)